5,0
1 dic 2015
Dipendente anonimo
Dipendente attuale, più di 10 anni
Nether Alderley, England
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Has a strong history in drug development and since the new CEO came on board the company is turning round after a significant dip in revenues. The portfolio is now looking very encouraging. Talented people and lots of career opportunities due to the size of the company.
Svantaggi
With a large portfolio and budget constraints there is more pressure on the staff so workloads can be high. The UK R&D hub will be in Cambridge in the future so whilst there is still a significant presence in the North West it will no longer have the same opportunities for those based in the North West.